You are here

P&T News

August 7

It’s All in How the Data Are Analyzed

July 31

Two Phase 3 Studies Met Endpoint of Complete Clearance of Lesions
Radiation Exposure Remains a Risk
Quality Metrics Will Provide Feedback to Manufacturers
Drugmaker Aiming for 25–30 New Drugs by 2022

July 24

Claims that tramiprosate helps stabilize patients over an 18-month period.
The biomarker can track a number of bodily functions.
Part of an ongoing effort to better oversee use of compounded medications.
HHS proposal designed to prevent ‘Shkrelis,’ not high drug prices overall
Some studies had linked the device to harmful side effects.

July 17

Some see the loss of an important, unbiased source of information.
Insurers are proceeding cautiously, but the large insurers are speeding up their approvals.
The move is considered part of the antiterrorism effort.
An impurity has been found to be carcinogenic.
But diabetes group tamp down expectations.

July 10

Agency says products for sexual enhancement, weight loss, and bodybuilding have hidden drugs and chemicals.
A meta-analysis that included 18 million participants found no protection from heart disease or stroke.
There is a small difference between them and biosimilars that physicians, patients, and insurers should be aware of.
It will nearly quadruple within the next five years, according to a new report, though concerns about how they’re manufactured remain.

Pages